Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Psoriasis
Interventions: Brodalumab; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 6
States / cities: Glendale, California • Aventura, Florida • Saint Paul, Minnesota + 3 more

Conditions: Psoriasis Vulgaris, Psoriatic Arthritis, Psoriasis
Interventions: Decision-Framed Survey; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Huntington Beach, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Genital Psoriasis, Psoriasis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Santa Ana, California • Santa Monica, California • Tampa, Florida + 9 more

Conditions: Psoriasis
Interventions: DFD06 Cream, Vehicle Cream; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Glendale, Arizona • Rogers, Arkansas • Fountain Valley, California + 26 more

Conditions: Psoriasis Vulgaris
Interventions: Not listed
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Phoenix, Arizona • Fremont, California • Clearwater, Florida + 9 more

Conditions: Psoriatic Arthritis
Interventions: Secukinumab 300 mg, Secukinumab 150 mg, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more

Conditions: Psoriasis
Interventions: Skin biopsy and blood test; Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Plaque Psoriasis
Interventions: 074-6751 Lotion; Device
Lead sponsor: Ferndale Laboratories, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more

Conditions: Psoriasis
Interventions: Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors); Biological · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,500 participants
Timeline: 2017 – 2031
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Psoriasis of Scalp
Interventions: Guselkumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: Apremilast (CC-10004), Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more

Conditions: Plaque Psoriasis
Interventions: Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 575 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 21,190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 167
States / cities: Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more

Conditions: Psoriasis
Interventions: Transitioning patients from cyclosporine to alefacept; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Psoriasis
Interventions: Corticosteroid, Placebo, LCD; Drug · Other
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Plaque Psoriasis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more

Conditions: Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions: KPL-716, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more

Conditions: Organ Transplant Rejection, Psoriasis
Interventions: Sustained Release Injectable Tacrolimus; Drug
Lead sponsor: Auritec Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Tucson, Arizona • Fountain Valley, California • La Mesa, California + 17 more

Conditions: Plaque Psoriasis
Interventions: 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Search by objective public record fields.

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

Impact of Decision-Framing in Psoriasis

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Comparative Analysis of Small and Large Plaque Psoriasis

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Immune Spatial Features of Guselkumab Cutaneous Response

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

Psoriasis Longitudinal Assessment and Registry

Transitioning From Cyclosporine to Alefacept in Psoriasis

Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects